Firehawk Liberty™ Receives Registration Approval in Egypt

Cairo, Egypt, 23 February 2022 - The Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), developed by Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®), recently received registration approval from the Central Administration for Pharmaceutical Affairs (CAPA) of Egypt. This is the second coronary product developed by MicroPort® to be approved in Egypt since it entered into the Egyptian market with the Firehawk Rapamycin Target Eluting Coronary Stent System in November 2019.

Firehawk Liberty™ is a drug-eluting stent (DES) that features strut in-groove coating and precision target drug-releasing patent technology. It combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy.

Firehawk Liberty™ allows for the precise release of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug, whilst significantly reducing the drug dosage. In addition, it features innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, thus further optimizing the vessel wall apposition.

Egypt is the third largest economy in Africa and an important hub country along the “Belt and Road” initiative. Firehawk Liberty™ is currently approved in a number of countries and regions, including Belarus, Saudi Arabia, South Korea, Brazil, Colombia, India and the European Union. In the future, MicroPort® will continue to adhere to its brand philosophy of ‘The Patient Always Comes First’ and work towards introducing more innovative medical devices to local markets to benefit patients around the world.

About Shanghai MicroPort Medical (Group) Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians with higher-quality, innovative high-end medical devices and integrated solutions.